Research & Literature

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

Tefferi A, Barbui T

American journal of hematology 2015; (90(2)):162-73 doi:10.1002/ajh.23895.

Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Arana Yi C, Tam CS, Verstovsek S

Future oncology (London, England) 2015; (11(5)):719-33 doi:10.2217/fon.14.272.

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

Pardanani A, Harrison C, Cortes JE, et al.

JAMA oncology 2015; (1(5)):643-51 doi:10.1001/jamaoncol.2015.1590.

Myeloproliferative Neoplasms: A Contemporary Review.

Tefferi A, Pardanani A

JAMA oncology 2015; (1(1)):97-105 doi:10.1001/jamaoncol.2015.89.

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.

McMullin MF, Harrison CN, Niederwieser D, et al.

Experimental hematology & oncology 2015; (4()):26 doi:10.1186/s40164-015-0021-2.

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.

Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al.

Blood 2016; (127(3)):325-32 doi:10.1182/blood-2015-07-661835.

Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.

Cerquozzi S, Tefferi A

Blood cancer journal 2015; (5()):e366 doi:10.1038/bcj.2015.95.

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.

Marty C, Pecquet C, Nivarthi H, et al.

Blood 2016; (127(10)):1317-24 doi:10.1182/blood-2015-11-679571.

Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.

Davis KL, Côté I, Kaye JA, et al.

Advances in hematology 2015; (2015()):848473 doi:10.1155/2015/848473.

[The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients].

Xu J, Xu Z, Wang J, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2016; (37(1)):26-9 doi:10.3760/cma.j.issn.0253-2727.2016.01.005.

Prognosis of Primary Myelofibrosis in the Genomic Era.

Bose P, Verstovsek S

Clinical lymphoma, myeloma & leukemia 2016; (16 Suppl()):S105-13.

Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.

Hart C, Klatt S, Barop J, et al.

Haematologica 2016; (101(11)):1407-1416 doi:10.3324/haematol.2016.146811.

Massive upper gastrointestinal bleeding due to splenoportal axis thrombosis in a patient with a tested JAK2 mutation: A case report and review literature.

Macías I

International journal of surgery case reports 2016; (28()):93-96 doi:10.1016/j.ijscr.2016.08.013.

Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.

Tefferi A

American journal of hematology 2016; (91(12)):1262-1271 doi:10.1002/ajh.24592.

Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013.

Byun JM, Kim YJ, Youk T, et al.

Annals of hematology 2017; (96(3)):373-381 doi:10.1007/s00277-016-2902-9.

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Guglielmelli P, Pacilli A, Rotunno G, et al.

Blood 2017; (129(24)):3227-3236 doi:10.1182/blood-2017-01-761999.

Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials.

Gwaltney C, Paty J, Kwitkowski VE, et al.

Leukemia research 2017; (59()):26-31 doi:10.1016/j.leukres.2017.05.012.

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

Passamonti F, Giorgino T, Mora B, et al.

Leukemia 2017; (31(12)):2726-2731 doi:10.1038/leu.2017.169.

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.

Masarova L, Bose P, Daver N, et al.

Leukemia research 2017; (59()):110-116 doi:10.1016/j.leukres.2017.06.001.

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

Harrison CN, Schaap N, Vannucchi AM, et al.

The Lancet. Haematology 2017; (4(7)):e317-e324 doi:10.1016/S2352-3026(17)30088-1.

Pre-PMF emerging as important subgroup of MPN.

Gisslinger H

Blood 2017; (129(24)):3142-3144 doi:10.1182/blood-2017-04-777805.

Impact of molecular residual disease post allografting in myelofibrosis patients.

Wolschke C, Badbaran A, Zabelina T, et al.

Bone marrow transplantation 2017; (52(11)):1526-1529 doi:10.1038/bmt.2017.157.

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.

Harrison CN, Koschmieder S, Foltz L, et al.

Annals of hematology 2017; (96(10)):1653-1665 doi:10.1007/s00277-017-3082-y.

Approach to MPN Symptom Assessment.

Geyer H, Mesa RA

Current hematologic malignancy reports 2017; (12(5)):381-388 doi:10.1007/s11899-017-0399-5.

Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.

Masarova L, Alhuraiji A, Bose P, et al.

European journal of haematology 2018; (100(3)):257-263 doi:10.1111/ejh.13005.

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

Guglielmelli P, Lasho TL, Rotunno G, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(4)):310-318 doi:10.1200/JCO.2017.76.4886.

Prognostic risk models for transplant decision-making in myelofibrosis.

Hernández-Boluda JC, Pereira A, Correa JG, et al.

Annals of hematology 2018; (97(5)):813-820 doi:10.1007/s00277-018-3240-x.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Barbui T, Tefferi A, Vannucchi AM, et al.

Leukemia 2018; (32(5)):1057-1069 doi:10.1038/s41375-018-0077-1.

Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.

Song MK, Park BB, Uhm JE

International journal of molecular sciences 2018; (19(3)) doi:10.3390/ijms19030898.

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.

Tefferi A, Guglielmelli P, Nicolosi M, et al.

Leukemia 2018; (32(7)):1631-1642 doi:10.1038/s41375-018-0107-z.

Diagnosis and management of prefibrotic myelofibrosis.

Rumi E, Sant'Antonio E, Boveri E, et al.

Expert review of hematology 2018; (11(7)):537-545 doi:10.1080/17474086.2018.1484280.

Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.

Tefferi A

American journal of hematology 2018; (93(12)):1551-1560 doi:10.1002/ajh.25230.

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎.

Palandri F, Palumbo GA, Iurlo A, et al.

Seminars in hematology 2018; (55(4)):248-255 doi:10.1053/j.seminhematol.2018.05.013.

20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients.

Penna D, Lasho TL, Finke CM, et al.

American journal of hematology 2019; (94(3)):286-290 doi:10.1002/ajh.25351.

Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation.

Gagelmann N, Ditschkowski M, Bogdanov R, et al.

Blood 2019; (133(20)):2233-2242 doi:10.1182/blood-2018-12-890889.

Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.

Gagelmann N, Eikema DJ, de Wreede LC, et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(6)):e204-e208 doi:10.1016/j.bbmt.2019.03.024.

Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation In Vivo.

Woods B, Chen W, Chiu S, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2019; (25(19)):5901-5912 doi:10.1158/1078-0432.CCR-18-4089.

Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

McLornan D, Szydlo R, Koster L, et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(11)):2167-2171 doi:10.1016/j.bbmt.2019.06.034.

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.

Bewersdorf JP, Jaszczur SM, Afifi S, et al.

Cancer management and research 2019; (11()):10777-10790 doi:10.2147/CMAR.S212559.

Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis.

Pastor-Galán I, Hernández-Boluda JC, Correa JG, et al.

Medicina clinica 2020; (155(4)):152-158 doi:10.1016/j.medcli.2019.11.007.

Myelofibrosis biology and contemporary management.

Gangat N, Tefferi A

British journal of haematology 2020; (191(2)):152-170 doi:10.1111/bjh.16576.

Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.

Hernández-Boluda JC, Pereira A, Kröger N, et al.

Leukemia 2021; (35(1)):215-224 doi:10.1038/s41375-020-0815-z.

Survival following allogeneic transplant in patients with myelofibrosis.

Gowin K, Ballen K, Ahn KW, et al.

Blood advances 2020; (4(9)):1965-1973 doi:10.1182/bloodadvances.2019001084.

Modern management of splenomegaly in patients with myelofibrosis.

Tremblay D, Schwartz M, Bakst R, et al.

Annals of hematology 2020; (99(7)):1441-1451 doi:10.1007/s00277-020-04069-4.

Myelofibrosis and Portal Hypertension: The Case for Primary Variceal Screening.

Sherman MS, Samore WR, Pratt DS

ACG case reports journal 2020; (7(2)):e00333 doi:10.14309/crj.0000000000000333.

Splenectomy in Myelofibrosis: Indications, Efficacy, and Complications.

Malato A, Rossi E, Tiribelli M, et al.

Clinical lymphoma, myeloma & leukemia 2020; (20(9)):588-595 doi:10.1016/j.clml.2020.04.015.

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.

Talpaz M, Kiladjian JJ

Leukemia 2021; (35(1)):1-17 doi:10.1038/s41375-020-0954-2.

Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.

Tefferi A

American journal of hematology 2021; (96(1)):145-162 doi:10.1002/ajh.26050.

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.

Gerds AT, Savona MR, Scott BL, et al.

Blood advances 2020; (4(22)):5825-5835 doi:10.1182/bloodadvances.2020003314.

Accelerated Phase of Myeloproliferative Neoplasms.

Shahin OA, Chifotides HT, Bose P, et al.

Acta haematologica 2021; (144(5)):484-499 doi:10.1159/000512929.

Next Generation Therapeutics for the Treatment of Myelofibrosis.

Tremblay D, Mascarenhas J

Cells 2021; (10(5)) doi:10.3390/cells10051034.

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.

Kröger N, Sbianchi G, Sirait T, et al.

Leukemia 2021; (35(12)):3551-3560 doi:10.1038/s41375-021-01276-4.

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.

Verstovsek S, Mesa R, Talpaz M, et al.

Haematologica 2022; (107(7)):1599-1607 doi:10.3324/haematol.2021.279415.

Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.

Barbui T, De Stefano V

Current hematologic malignancy reports 2021; (16(5)):455-463 doi:10.1007/s11899-021-00647-z.

Liver infarct masquerading as intrahepatic cholangiocarcinoma.

Fariduddin MM, Syed W, Birjees A, Naqvi MR

Proceedings (Baylor University. Medical Center) 2021; (34(6)):693-695 doi:10.1080/08998280.2021.1930968.

Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular Determinants.

Sabattini E, Pizzi M, Agostinelli C, et al.

Cancers 2021; (13(21)) doi:10.3390/cancers13215531.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

Devos T, Selleslag D, Granacher N, et al.

Hematology (Amsterdam, Netherlands) 2022; (27(1)):23-31 doi:10.1080/16078454.2021.2009645.

Osteolytic bone lesions in patients with primary myelofibrosis: A systematic review.

Battukh N, Ali E, Yassin M

Acta bio-medica : Atenei Parmensis 2022; (92(6)):e2021478 doi:10.23750/abm.v92i6.12350.

Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.

Pasca S, Chifotides HT, Verstovsek S, Bose P

International review of cell and molecular biology 2022; (366()):83-124 doi:10.1016/bs.ircmb.2021.02.008.

How I Diagnose Primary Myelofibrosis.

Prakash S, Orazi A

American journal of clinical pathology 2022; (157(4)):518-530 doi:10.1093/ajcp/aqac016.

Transfusion Independence Achieved with Combination Fedratinib and Luspatercept in an Elderly Man with Heavily Pretreated Intermediate-2 Risk Primary Myelofibrosis.

Yun NK, Alrifai T, Miller IJ, Shammo JM

Case reports in oncology 2022; (15(1)):126-132 doi:10.1159/000521889.

Primary Myelofibrosis in the Prefibrotic Stage Presenting as Portal, Splenic, and Superior Mesenteric Vein Thrombosis: A Case Report and Review of the Literature.

Dias E, Liberal R, Costa-Moreira P, et al.

GE Portuguese journal of gastroenterology 2022; (29(2)):125-131 doi:10.1159/000514658.

Practical management of the haemorrhagic complications of myeloproliferative neoplasms.

Jones E, Dillon B, Swan D, Thachil J

British journal of haematology 2022; (199(3)):313-321 doi:10.1111/bjh.18322.

Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms.

Papageorgiou L, Elalamy I, Vandreden P, Gerotziafas GT

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2022; (28()):10760296221097969 doi:10.1177/10760296221097969.

Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.

Mora B, Passamonti F

Current hematologic malignancy reports 2022; (17(5)):127-139 doi:10.1007/s11899-022-00672-6.

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Gerds AT, Gotlib J, Ali H, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(9)):1033-1062.

The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.

Thiele J, Kvasnicka HM, Orazi A, et al.

American journal of hematology 2023; (98(1)):166-179 doi:10.1002/ajh.26751.

Accelerated and blast phase myeloproliferative neoplasms.

Saliba AN, Gangat N

Best practice & research. Clinical haematology 2022; (35(2)):101379 doi:10.1016/j.beha.2022.101379.

Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry.

Góra-Tybor J, Gołos A, Mikulski D, et al.

Clinical lymphoma, myeloma & leukemia 2023; (23(1)):e19-e26 doi:10.1016/j.clml.2022.10.002.

New approaches to tackle cytopenic myelofibrosis.

Reynolds SB, Pettit K

Hematology. American Society of Hematology. Education Program 2022; (2022(1)):235-244 doi:10.1182/hematology.2022000340.

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.

Tefferi A

American journal of hematology 2023; (98(5)):801-821 doi:10.1002/ajh.26857.

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.

Verstovsek S, Gerds AT, Vannucchi AM, et al.

Lancet (London, England) 2023; (401(10373)):269-280 doi:10.1016/S0140-6736(22)02036-0.

Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.

Murthy GSG, Kim S, Estrada-Merly N, et al.

Haematologica 2023; (108(7)):1900-1908 doi:10.3324/haematol.2022.281958.

Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges.

Ajufo HO, Waksal JA, Mascarenhas JO, Rampal RK

Therapeutic advances in hematology 2023; (14()):20406207231177282 doi:10.1177/20406207231177282.

Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group.

Gill H, Leung GMK, Ooi MGM, et al.

Clinical and experimental medicine 2023; (23(8)):4199-4217 doi:10.1007/s10238-023-01189-9.

Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.

Kröger N, Bacigalupo A, Barbui T, et al.

The Lancet. Haematology 2024; (11(1)):e62-e74 doi:10.1016/S2352-3026(23)00305-8.

Treatment of anemia in myelofibrosis: focusing on novel therapeutic options.

Arslan Davulcu E, Oğuz MB, Kılıç E, Eşkazan AE

Expert opinion on investigational drugs 2024; (33(1)):27-37 doi:10.1080/13543784.2023.2294324.

STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient.

Zhang S, Yan J, He L, et al.

Cancer gene therapy 2024; (31(3)):484-494 doi:10.1038/s41417-023-00719-7.

Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis.

Gagelmann N, Hobbs GS, Campodonico E, et al.

American journal of hematology 2024; (99(5)):844-853 doi:10.1002/ajh.27252.

A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery.

Andreescu M, Andreescu B

Cureus 2024; (16(3)):e56008 doi:10.7759/cureus.56008.

Acute upper gastrointestinal bleeding due to portal hypertension in a patient with primary myelofibrosis: A case report.

Chen Y, Kong BB, Yin H, et al.

World journal of clinical cases 2024; (12(15)):2621-2626 doi:10.12998/wjcc.v12.i15.2621.

Momelotinib: Mechanism of action, clinical, and translational science.

Vlasakakis G, McCabe MT, Ho YL, et al.

Clinical and translational science 2024; (17(8)):e70018 doi:10.1111/cts.70018.

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.

Harrison CN, Mesa R, Talpaz M, et al.

The Lancet. Haematology 2024; (11(10)):e729-e740 doi:10.1016/S2352-3026(24)00212-6.

How I individualize selection of JAK inhibitors for patients with myelofibrosis.

Masarova L, Chifotides HT

Blood 2025; (145(16)):1724-1737 doi:10.1182/blood.2023022415.

SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis.

Hochman MJ, Vale CA, Hunter AM

Clinical lymphoma, myeloma & leukemia 2025; (25(4)):226-239 doi:10.1016/j.clml.2024.09.001.

Spatial-transcriptomic profiling: a new lens for understanding myelofibrosis pathophysiology.

Peroni E, Calistri E, Amato R, et al.

Cell communication and signaling : CCS 2024; (22(1)):510 doi:10.1186/s12964-024-01877-3.

SOHO State of the Art Updates and Next Questions | Updates on Myelofibrosis With Cytopenia.

Khan MA, Palmer J

Clinical lymphoma, myeloma & leukemia 2025; (25(5)):293-303 doi:10.1016/j.clml.2024.09.002.

Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.

Harrison CN, Mesa R, Talpaz M, et al.

Clinical lymphoma, myeloma & leukemia 2025; (25(3)):199-211 doi:10.1016/j.clml.2024.10.001.

Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.

Luque Paz D, Gagelmann N, Benajiba L, et al.

Blood advances 2025; (9(4)):797-807 doi:10.1182/bloodadvances.2024014368.

Spleen volume assessment in Ph-negative chronic myeloproliferative neoplasms: a real-life study comparing ultrasonography vs. magnetic resonance imaging scans.

Pugliese N, Cavaliere C, Basso L, et al.

Annals of hematology 2025; (104(1)):383-388 doi:10.1007/s00277-024-06177-x.

Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification.

Thiele J, Kvasnicka HM, Gianelli U, et al.

Blood cancer journal 2025; (15(1)):31 doi:10.1038/s41408-025-01235-7.

Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes.

Gangat N, Tefferi A

American journal of hematology 2025; (100 Suppl 4()):51-65 doi:10.1002/ajh.27659.

Myelofibrosis: Timing of Transplantation and Management of Splenomegaly.

Kröger N, Rathje K, Gagelmann N

Advances in experimental medicine and biology 2025; (1475()):167-175 doi:10.1007/978-3-031-84988-6_9.

Diffuse FAPI-46 Uptake in Bone Marrow: A Case of Primary Myelofibrosis With Superscan Pattern on Bone Scintigraphy.

Elahifard H, Raeisi N, Saber Tanha A, et al.

Clinical nuclear medicine 2025; (50(12)):e686-e688 doi:10.1097/RLU.0000000000005862.

CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in Myelofibrosis.

Mirabile M, Tombari C, Neroni A, et al.

Journal of cellular and molecular medicine 2025; (29(14)):e70720 doi:10.1111/jcmm.70720.

From symptom scales to regulatory endpoints: the evolution and clinical impact of patient-reported outcome measures in myeloproliferative neoplasms.

Chen M, Zheng C, Xie J, et al.

Clinical and experimental medicine 2025; (25(1)):330 doi:10.1007/s10238-025-01830-9.

Incidence and risk factors for graft failure after allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.

Sun Y, Zhu J, Chen J, et al.

Bone marrow transplantation 2026; (61(2)):159-165 doi:10.1038/s41409-025-02746-4.

Myelofibrosis-associated extramedullary hematopoiesis: Insights into hepatic, pulmonary, and thrombotic complications.

Amanam I, Otoukesh S, Pullarkat V, et al.

Blood reviews 2026; (75()):101355 doi:10.1016/j.blre.2025.101355.

A Review of the Pathological and Molecular Diagnosis of Primary Myelofibrosis.

Shao R, Ryder C, Wang L, et al.

Cancers 2025; (18(1)) doi:10.3390/cancers18010050.

Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.

De Fazio L, Molica M, Simio C, Rossi M

Leukemia & lymphoma 2026; (67(6)):1257-1267 doi:10.1080/10428194.2026.2655442.

Cardiac Tamponade-A Rare Manifestation of Ruxolitinib Discontinuation Syndrome: A Case Report.

Hamid S, Bennet R, Yao J, Wong J

Case reports in cardiology 2026; (2026()):8854255 doi:10.1155/cric/8854255.

Targeted treatment of anemia in myelofibrosis and the impact of JAK inhibitors.

Al Noumani I, Harrison C

Expert opinion on pharmacotherapy 2026; (27(8)):657-668 doi:10.1080/14656566.2026.2671877.

JAK2 V617F as a diagnostic and prognostic biomarker in myeloproliferative neoplasms.

Bhat AA, Fuloria S, Thapa R, et al.

Clinica chimica acta; international journal of clinical chemistry 2026; (590()):121116 doi:10.1016/j.cca.2026.121116.

Spontaneous bacterial peritonitis in non-cirrhotic portal hypertension secondary to primary myelofibrosis: A rare case report.

Pradana FR, Nuramalia LS, Maimunah U

iLIVER 2026; (5(2)):100239 doi:10.1016/j.iliver.2026.100239.

Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.

Griesshammer M, Al-Ali HK, Baerlocher GM, et al.

International journal of cancer 2026; (159(7)):1642-1662 doi:10.1002/ijc.70596.